Presentation is loading. Please wait.

Presentation is loading. Please wait.

Zacho J, et al. N Engl J Med 2008;359:1897-908 Risk of Ischemic Heart Disease as a Function of Plasma Levels of C-Reactive Protein (CRP) in the General.

Published byHortense Sanders Modified over 9 years ago

Similar presentations

Presentation on theme: "Zacho J, et al. N Engl J Med 2008;359:1897-908 Risk of Ischemic Heart Disease as a Function of Plasma Levels of C-Reactive Protein (CRP) in the General."— Presentation transcript:

1 Zacho J, et al. N Engl J Med 2008;359:1897-908 Risk of Ischemic Heart Disease as a Function of Plasma Levels of C-Reactive Protein (CRP) in the General Population

2 Risk of Ischemic Cerebrovascular Disease as a Function of Plasma Levels of C-Reactive Protein (CRP) in the General Population Zacho J, et al. N Engl J Med 2008;359:1897-908

3 Plasma Levels of C-Reactive Protein (CRP) as a Function of CRP Genotype and Genotype Combination in the General Population Zacho J, et al. N Engl J Med 2008;359:1897-908

4 Risk of Ischemic Heart Disease as a Function of C-Reactive Protein (CRP) Genotype and Genotype Combination Zacho J, et al. N Engl J Med 2008;359:1897-908

5 Risk of Ischemic Cerebrovascular Disease as a Function of C-Reactive Protein (CRP) Genotype and Genotype Combination Zacho J, et al. N Engl J Med 2008;359:1897-908

6 Summary of Studies of the Effect of C-Reactive Protein (CRP) Genotype Combination and Apolipoprotein E Genotype on the Risk of Ischemic Heart Disease (IHD) Zacho J, et al. N Engl J Med 2008;359:1897-908

7 Summary of Studies of the Effect of C-Reactive Protein (CRP) Genotype Combination on the Risk of Ischemic Cerebrovascular Disease (ICVD) Zacho J, et al. N Engl J Med 2008;359:1897-908

Download ppt "Zacho J, et al. N Engl J Med 2008;359:1897-908 Risk of Ischemic Heart Disease as a Function of Plasma Levels of C-Reactive Protein (CRP) in the General."

Similar presentations

Blood Pressure and Diabetes Colin M. Dayan University of Bristol/UBHT.

Blood Pressure and Diabetes Colin M. Dayan University of Bristol/UBHT.
Nonsense Mutations in PCSK9 and Cardiovascular Risk Factors among 3363 Black Participants in the Study Jonathan C.Cohen, et al, N Engl J Med 2006;354:1264-72.

Nonsense Mutations in PCSK9 and Cardiovascular Risk Factors among 3363 Black Participants in the Study Jonathan C.Cohen, et al, N Engl J Med 2006;354:
Cholesterol quintile (mg/dL)

Cholesterol quintile (mg/dL)
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
(N=488) Simvastatin in Patients With Prior Cerebrovascular Disease: HPS *29% RRR, p=0.001 Heart Protection Study Collaborative Group. Lancet. 2004;363:757-767.

(N=488) Simvastatin in Patients With Prior Cerebrovascular Disease: HPS *29% RRR, p=0.001 Heart Protection Study Collaborative Group. Lancet. 2004;363:
Randomized, double-blind, multicenter, controlled trial.

Randomized, double-blind, multicenter, controlled trial.
Frank B. Hu et al N Engl J Med 2004; 351: 2694- 703 Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.

Frank B. Hu et al N Engl J Med 2004; 351: Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.
STROKE STATS Third leading cause of death 160 000 deaths a year 731 000 strokes a year 4 400 000 stroke survivors Leading cause of adult disability Source:

STROKE STATS Third leading cause of death deaths a year strokes a year stroke survivors Leading cause of adult disability Source:
VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.

VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.
Glynn RJ, et al. N Engl J Med 2009 Mar 29 [Epub ahead of print]

Glynn RJ, et al. N Engl J Med 2009 Mar 29 [Epub ahead of print]
Baseline Characteristics of Individuals From the General Population by Quartiles of Triglyceride Levels a Børge G. Nordestgaard, et al. JAMA 2007;298:299-308.

Baseline Characteristics of Individuals From the General Population by Quartiles of Triglyceride Levels a Børge G. Nordestgaard, et al. JAMA 2007;298:
Pai JK et al. N Engl J Med 2004; 351:2599-2610. Relative CHD risk by increasing baseline CRP plasma levels,* relative to CRP

Pai JK et al. N Engl J Med 2004; 351: Relative CHD risk by increasing baseline CRP plasma levels,* relative to CRP
From Genome-Wide Association Studies to Medicine Florian Schmitzberger - CS 374 – 4/28/2009 Stanford University Biomedical Informatics

From Genome-Wide Association Studies to Medicine Florian Schmitzberger - CS 374 – 4/28/2009 Stanford University Biomedical Informatics
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
Demographic Characteristics of the Study Population - Part I Jenny N.Poynter et al N Engl J Med 2005;352:2184- 92.

Demographic Characteristics of the Study Population - Part I Jenny N.Poynter et al N Engl J Med 2005;352:
Solomon Tesfaye et al N Engl J Med 2005;352:341- 50 Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.

Solomon Tesfaye et al N Engl J Med 2005;352: Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.
Slide Source: Lipids Online Slide Library www.lipidsonline.org LDL Cholesterol, mg/dL Years of Follow-up Ridker PM et al. N Engl J Med 2002;347:1557–1565.

Slide Source: Lipids Online Slide Library LDL Cholesterol, mg/dL Years of Follow-up Ridker PM et al. N Engl J Med 2002;347:1557–1565.
Age-standardized mortality from ischaemic heart disease in European regions (men; age group 45-74 years; year 2000) J Muller-Nordhorn, et al. Eur Heart.

Age-standardized mortality from ischaemic heart disease in European regions (men; age group years; year 2000) J Muller-Nordhorn, et al. Eur Heart.
Ridker PM, et al. Lancet 2009;373:1175-82. Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.

Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.
Interleukin 6 pathway and coronary heart disease

Interleukin 6 pathway and coronary heart disease

Similar presentations

Ads by Google